Pharmicell Co., Ltd. (KRX:005690)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,240
-990 (-5.75%)
Last updated: Feb 27, 2026, 3:19 PM KST
45.91%
Market Cap 974.47B
Revenue (ttm) 23.94B
Net Income (ttm) -26.78B
Shares Out 60.00M
EPS (ttm) -613.75
PE Ratio n/a
Forward PE n/a
Dividend 50.00 (0.31%)
Ex-Dividend Date Dec 29, 2025
Volume 1,347,281
Average Volume 2,216,927
Open 16,830
Previous Close 17,230
Day's Range 16,170 - 17,100
52-Week Range 8,150 - 20,800
Beta 0.51
RSI 53.19
Earnings Date n/a

About Pharmicell

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1968
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 005690
Full Company Profile

Financial Performance

In 2013, Pharmicell's revenue was 33.41 billion, an increase of 200.63% compared to the previous year's 11.11 billion. Losses were -25.70 billion, 45.7% more than in 2012.

Financial Statements

News

There is no news available yet.